SCM
ELVN icon

Soleus Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Soleus Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.41M Sell
165,677
-65,192
-28% -$2.77M 0.29% 64
2026
Q1 		$9.05M Sell
230,869
-794,131
-77% -$22M 0.37% 55
2025
Q4 		$15.8M Buy
+1,025,000
New +$20.4M 0.58% 44
2025
Q1 		– Sell
-75,405
Closed -$1.7M – 82
2024
Q4 		$1.7M Sell
75,405
-164,300
-69% -$4.26M 0.11% 69
2024
Q3 		$6.12M Sell
239,705
-529,558
-69% -$12.3M 0.47% 51
2024
Q2 		$18M Buy
+769,263
New +$16.2M 1.59% 24

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Soleus Capital Management's ELVN Position: Q2 2026 in Review

Soleus Capital Management reduced its Enliven Therapeutics (ELVN) stake by 28% in Q2 2026, selling an estimated $2.77M and leaving 165,677 shares worth $8.41M. The position accounts for 0.29% of the portfolio, ranked #64.

Soleus Capital Management first reported a position in ELVN in Q2 2024 and has held it in 6 quarters since. The position peaked at $18M in Q2 2024. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Soleus Capital Management held 165,677 shares of Enliven Therapeutics worth $8.41M as of Q2 2026.
  • Soleus Capital Management sold 65,192 Enliven Therapeutics shares in Q2 2026, an estimated $2.77M.
  • Enliven Therapeutics made up 0.29% of Soleus Capital Management's portfolio in Q2 2026, its #64 holding.
  • Soleus Capital Management first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Soleus Capital Management's Enliven Therapeutics position peaked at $18M in Q2 2024.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.